Vigeo Therapeutics To Present New Phase 1/2 VT1021 Dose Escalation And Expansion Data At The Society For Immunotherapy Of Cancer's 2020 Annual Meeting

Press/Media: Press / Media

PeriodNov 9 2020

Media coverage

2

Media coverage

  • TitleVigeo Therapeutics To Present New Phase 1/2 VT1021 Dose Escalation And Expansion Data At The Society For Immunotherapy Of Cancer's 2020 Annual Meeting
    Media name/outletTheStreet.com
    CountryUnited States
    Date11/9/20
    PersonsDevalingam Mahalingam
  • TitleVigeo Therapeutics to Present New Phase 1/2 VT1021 Dose Escalation and Expansion Data at the Society for Immunotherapy of Cancer's 2020 Annual Meeting; 75% of Patients Who Achieved a Partial Response or Stable Disease Had High Expression of Both CD47 and
    Media name/outletPR Newswire
    CountryUnited States
    Date11/9/20
    PersonsDevalingam Mahalingam